_Clinical_Trials_Market.JPG)
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Size is valued at USD 19.49 Bn in 2023 and is predicted to reach USD 33.61 Bn by the year 2031 at a 7.20% CAGR during the forecast period for 2024-2031.
Clinical trials regarding Chronic Obstructive Pulmonary Disease (COPD) are research studies designed to investigate and test new treatments, medications, interventions, and approaches to better understand, manage, and potentially cure COPD. The market for clinical trials for chronic obstructive pulmonary disease (COPD) is related to the pharmaceutical and medical research industries. It is centred on the creation and assessment of COPD treatment options. Clinical trials for COPD explore possible treatments, medications, and other interventions to enhance patient outcomes and management. These studies evaluate new drugs or treatment approaches for adverse effects, safety, and effectiveness. The market is growing to meet the increasing demand for cutting-edge treatments as COPD is becoming more commonplace worldwide. It is essential for expanding medical knowledge, improving patient care, and introducing novel COPD medicines to the market, all of which help to improve the quality of life for those who suffer from this chronic illness.
However, increasing public awareness throughout developing and underdeveloped regions is also expected to assist the market's rise, and rising healthcare spending is providing facilities for COPD in developing countries. Moreover, a significant aspect expected to drive the industry's progress in chronic obstructive pulmonary disease is increased research and development spending by big corporations and the government. In emphysema patients, the alveoli in the lungs are damaged. The lungs enlarge and become harder to breathe through due to the stretched alveolar walls. Chronic bronchitis irritates the bronchial airways in the lungs.
Competitive Landscape
Some Major Key Players In The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market:
- AstraZeneca
- Boehringer Ingelheim International GmbH
- CHIESI Pharmaceutics S.p.A.
- Glaxo SmithKline plc
- Mylan N.V.
- Novartis AG
- Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.
- Almirall
- Astellas Pharma
- Sanofi
- Others
Market Segmentation:
The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market is segmented according to drug class, type, and distribution channel. As per the Drug Class, the market is segmented as Bronchodilators, Combination, Corticosteroids, and Phosphodiesterase. The application segment includes Chronic Bronchitis and Emphysema. The Distribution Channel segment is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
Based On Product, The Bronchodilators Segment Is A Major Contributor In The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market.
The Bronchodilators category will hold a major share of the global market in 2024. A class of drugs called bronchodilators helps people with COPD relax their airways, and this is one of the main factors driving the Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market's expansion. Intending to give COPD patients better relief, these trials concentrate on creating safer and more effective bronchodilators. There is an urgent need for novel treatments due to the rising global prevalence of COPD. It has attracted significant attention because bronchodilator research can improve the standard of life and respiratory function of individuals with COPD. To meet this need, bronchodilator-related clinical studies are leading the way and providing hope for improved COPD care management and results.
The Hospital Pharmacies Segment Witnessed Rapid Growth.
Hospital Pharmacies is the segment which is projected to grow rapidly in the global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market. By providing key infrastructure and experience, hospital pharmacies play a critical role in the growth of the Chronic Obstructive Pulmonary Disease (COPD) clinical trials industry. They provide controlled conditions for drug delivery and monitoring, assuring the safety of patients. Hospital pharmacists also handle drug dispensing, compliance, and data gathering, allowing clinical studies to go smoothly. Furthermore, their proximity to healthcare professionals and patients simplifies recruiting and patient care, resulting in faster trial processes. In essence, hospital pharmacies act as critical collaborators in expanding COPD clinical trials, which are critical for developing treatment options and improving the lives of COPD patients.
The North American Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Holds A Significant Revenue Share In The Region.
The North American Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market is expected to register the highest market share in revenue shortly. Several factors are driving growth in North America's Chronic Obstructive Pulmonary Disease (COPD) clinical trials market. There is a significant prevalence of COPD in the region, as well as a well-established healthcare infrastructure, robust research capacity, and a huge patient pool. Furthermore, governmental assistance and a good investment climate make North America an appealing site for pharmaceutical companies, fueling the region's expansion of COPD clinical trials. In addition, Asia Pacific is estimated to grow rapidly in the global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market. Asia Pacific's expansion in the COPD clinical trials market is driven by the region's vast, diversified population, rising COPD cases, cheaper research costs, and increased investments in healthcare infrastructure and research, enticing pharmaceutical companies to perform studies there.
Recent Developments:
- In March 2023, A Phase 3 clinical trial for chronic obstructive pulmonary disease was successfully concluded by Sanofi and Regeneron with their anti-inflammatory medication. This accomplishment presents Dupixent, the medication, with the chance to become the inaugural biologic therapy to obtain authorization for the condition.
- In April 2022, GlaxoSmithKline Pharmaceuticals introduced Trelegy Ellipta for people with COPD. Trelegy Ellipta is India's first once-daily single-inhaler triple treatment (SITT) for COPD patients.
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 19.49 Bn |
|
Revenue Forecast In 2031 |
USD 33.61 Bn |
|
Growth Rate CAGR |
CAGR of 7.20 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, Type, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Pharmaceutics S.p.A., Glaxo SmithKline plc, Mylan N.V., Novartis AG, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Almirall, Astellas Pharma, Sanofi and others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
